Merck announces additional approvals for Keytruda®

Merck announces Keytruda® (pembrolizumab) has received two additional approvals from the Japanese Pharmaceuticals and Medical Devices Agency:

• new indication for the treatment of patients whose tumours are PD-L1-positive, and have radically unresectable, advanced or recurrent esophageal squamous cell carcinoma;

• and an additional dosage regimen of 400mg every six weeks as an IV infusion over 30 minutes, across all adult indications.